🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Alex Horsley

University of Manchester

ORCID: 0000-0003-1828-0058

Also affiliated with Manchester University NHS Foundation Trust, NIHR Manchester Biomedical Research Centre

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

3in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology
Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 3 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 8 papers. Top paper: “Vanzacaftor–tezacaftor–deutivacaftor versus elexacaftor–tezacaftor–ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials”.

Vanzacaftor–tezacaftor–deutivacaftor versus elexacaftor–tezacaftor–ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials

The Lancet Respiratory Medicine(2025)10.1016/s2213-2600(24)00411-9
N/A
1.9DataRank · unranked
95 citations

Lael M. Yonker, F. Vermeulen, Dario Prais, Rachel W. Linnemann, Aaron Trimble +92 more

Safety and efficacy of vanzacaftor–tezacaftor–deutivacaftor in adults with cystic fibrosis: randomised, double-blind, controlled, phase 2 trials

The Lancet Respiratory Medicine(2023)10.1016/s2213-2600(22)00504-5
N/A
1.5DataRank · unranked
67 citations

Gordon MacGregor, Pilar Azevedo, V. Indihar, Claire Keating, Marcus Mall +77 more

Advances in COPD imaging using CT and MRI: linkage with lung physiology and clinical outcomes

European Respiratory Journal(2024)10.1183/13993003.01010-2023
N/A
0.489DataRank · unranked
25 citations

Helen Marshall, Josephine H. Naish, Jim M. Wild, Grace Párraga, Alex Horsley +2 more

Empire-CF study: A phase 2 clinical trial of leukotriene A4 hydrolase inhibitor acebilustat in adult subjects with cystic fibrosis

Journal of Cystic Fibrosis(2021)10.1016/j.jcf.2021.08.007
N/A
0.464DataRank · unranked
21 citations

Michael W. Konstan, Jennifer L. Taylor‐Cousar, Isabelle Fajac, Alex Horsley, Sivagurunathan Sutharsan +11 more

Reassessment of the importance of mucins in determining sputum properties in cystic fibrosis

Journal of Cystic Fibrosis(2014)10.1016/j.jcf.2013.11.002
N/A
0.464DataRank · unranked
21 citations

Karine Rousseau, Caroline Ridley, William Flight, Andrew Jones, Thomas A. Waigh +2 more

Burkholderia latens infection in cystic fibrosis

Journal of Cystic Fibrosis(2011)10.1016/j.jcf.2011.01.001
N/A
0.292DataRank · unranked
6 citations

Claire Perry, Kate Martin, Kevin Webb, Jane Turton, Dervla Kenna +2 more

192 Gastrointestinal symptoms in a cystic fibrosis transmembrane conductance regulator modulator era—an international survey

Journal of Cystic Fibrosis(2022)10.1016/s1569-1993(22)00882-7
N/A
0DataRank · unranked
8 citations

B. Hayee, L. Howells, Zoe Elliott, Alex Horsley, N. Goodchild +9 more

Future therapies for cystic fibrosis

Nature Communications(2023)10.1038/s41467-023-36244-2
N/A
0DataRank · unranked
136 citations

Lorna Allen, S.B. Carr, Gwyneth Davies, D.G. Downey, Marie E. Egan +8 more